Clinical trials
Intermittent Claudication trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2021 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Philips Clinical & Medical Affairs Global | 3 |
| 480 Biomedical | 2 |
| Paracelsus Medical University | 2 |
| Abbott Medical Devices | 1 |
| Hemoteq AG | 1 |
| Institut für Klinisch-Kardiovaskuläre Forschung GmbH | 1 |
| R3 Vascular Inc. | 1 |
| Sanofi | 1 |
| Siemens Healthineers Endovascular Robotics, Inc. | 1 |
| TriReme Medical, LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Intermittent Claudication | 15 |
| Peripheral Arterial Disease | 9 |
| Atherosclerosis | 3 |
| Cardiovascular Diseases | 2 |
| Chronic Limb-Threatening Ischemia | 2 |
| Peripheral Vascular Diseases | 2 |
| Vascular Diseases | 2 |
| Arteriosclerosis | 1 |
| Disease | 1 |
| Ischemia | 1 |
Trials
Showing 76 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.